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AustraliaBackground: There is uncertainty about the impact of severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
infection in individuals with rare inborn errors of immunity
(IEI), a population at risk of developing severe coronavirus
disease 2019. This is relevant not only for these patients but also
for the general population, because studies of IEIs can unveil
key requirements for host defense.
Objective: We sought to describe the presentation,
manifestations, and outcome of SARS-CoV-2 infection in IEI to
inform physicians and enhance understanding of host defense
against SARS-CoV-2.
Methods: An invitation to participate in a retrospective study
was distributed globally to scientific, medical, and patient
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520Results: We gathered information on 94 patients with IEI
with SARS-CoV-2 infection. Their median age was 25 to 34
years. Fifty-three patients (56%) suffered from primary
antibody deficiency, 9 (9.6%) had immune dysregulation
syndrome, 6 (6.4%) a phagocyte defect, 7 (7.4%) an
autoinflammatory disorder, 14 (15%) a combined
immunodeficiency, 3 (3%) an innate immune defect, and 2
(2%) bone marrow failure. Ten were asymptomatic, 25 were
treated as outpatients, 28 required admission without
intensive care or ventilation, 13 required noninvasive
ventilation or oxygen administration, 18 were admitted to
intensive care units, 12 required invasive ventilation, and 3
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of patients with IEI had mild coronavirus disease 2019 (COVID-
19) and (2) risk factors predisposing to severe disease/mortality
in the general population also seemed to affect patients with IEI,
including more younger patients. Further studies will identify
pathways that are associated with increased risk of severe
disease and are nonredundant or redundant for protection
against SARS-CoV-2. (J Allergy Clin Immunol 2021;147:520-
31.)
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In December 2019, the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), a single-stranded RNA virus,
emerged in the Hubei province of China as a novel human
pathogen. SARS-CoV-2 causes an infectious disease (coronavirus
disease 2019 [COVID-19]) characterized by pneumonia and
acute respiratory failure.1-4 SARS-CoV-2 infects human cells
by binding to the angiotensin-converting enzyme 2, which is ex-
pressed predominantly by lung and intestinal epithelial cells,
alveolar cells, and vascular endothelial cells. SARS-CoV-2
spreads within the human populationmainly via droplet transmis-
sion and has infected more than 40 million individuals,
causing more than 1.1 million deaths. There is a broad clinical
spectrum including asymptomatic infection, mild infection (fe-
ver, fatigue, diarrhea, vomiting, myalgia, dry cough, dyspnea,
and pneumonia), respiratory failure, myocarditis, thromboembo-
lism, and finally fatal multiorgan failure.5,6 The pathophysiology
of COVID-19 results from direct cytopathic effects of
SARS-CoV-2 on respiratory epithelia, endothelia, and other
organ-specific cell types, and subsequent induction of a proin-
flammatory cytokine storm and dysregulated adaptive immunity
causing severe tissue damage.7
Current epidemiology studies indicate that the case-fatality
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ability, the lethality of SARS-CoV-2 infection consistently and
dramatically increases with each decade of life beyond age
50 years10 (Table I). Furthermore, pre-existing comorbidities
(chronic lung/heart disease, obesity, diabetes, hypertension)
have been reported to contribute to a more severe course of
COVID-19.11,12 Importantly, the occurrence of a multisystemic
hyperinflammatory syndrome in children (MIS-C) has chal-
lenged the perception that SARS-CoV-2 infection is mild in
young individuals.13,14 In most countries, more males than
females have presented with symptomatic SARS-CoV-2 infec-
tion, indicating that sex can influence disease course and/or
outcome.10
Another contributor to interindividual susceptibility to severe
COVID-19 and outcome postinfection is genetic heterogeneity.15
This reflects the discoveries of patients with inborn errors of
immunity (IEI) who exhibit increased susceptibility to pathogenzzSt Vincent’s Clinical School, UNSW Sydney, Darlinghurst; and aaaHospital Roberto
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TABLE I. Age distribution and lethality of SARS-CoV-2 infection in patients with IEI




























0-2 6:1 7 (7.4) 1 of 7 (14) 3 of 7 (43) 0-9 1.5* 4.2 0.1* 0 0.7*
3-12 12:5 17 (18) 0 of 17 2 of 17 (12)
13-18 4:4 8 (8.5) 1 of 8 (10) 4 of 8 (50) 10-19 3.7 7.8 0.1 0.2 0.4
19-24 4:0 4 (4.2) 0 of 4 0 of 4 20-29 13.8 20.0 0.1 0.2 0.5
25-34 10:3 13 (13.8) 0 of 13 0 of 13 30-39 16.3 17.8 0.4 0.2 0.9
35-44 9:6 15 (16) 2 of 15 (13) 3 of 15 (20) 40-49 16.6 14.4 1.0 0.3 1.5
45-54 8:1 9 (9.5) 0 of 0 1 of 9 (11) 50-59 17.9 12.7 2.4 0.8 2.5
55-64 5:5 10 (10.6) 2 of 10 (20) 3 of 10 (30) 60-69 13.6 7.6 6.7 2.7 4.1
65-74 0:5 5 (5.3) 0 0 70-79 8.0 5.3 16.6 8.0 5.6
>75 2:3 5 (5.3) 3 (60) 2 (40) >80 8.7 10.0 28.7 16.0 3.6
All patients 65:35
(1.8:1)
NA 10 (10) 20 (20) All 5.4 (1-20) 2.3
F, Female; M, male; N, absolute number.
Data for the general population are all taken from Stokes et al.10
*Data from the United States, n 5 1,320,488 cases.10
Data from the United Kingdom, n5 73,359 cases (https://www.gov.uk/government/publications/demographic-data-for-coronavirus-testing-england-28-may-to-26-august/
demographic-data-for-coronavirus-covid-19-testing-england-28-may-to-26-august).
https://ourworldindata.org/covid-deaths; average of data from Spain, Italy, China, and South Korea.
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described,16-18 the consequences of SARS-CoV-2 infection have
been reported for only a few individuals with these
conditions.19-22
Thus, the aim of this multicenter, retrospective international
study was to assess the impact of SARS-CoV-2 infection on
patients with IEIs, thereby providing the first comprehensive
description on the susceptibility of an at-risk population of
patients to SARS-CoV-2 infection, as well as their COVID-19
clinical course, severity, complications, and outcomes. This
extensive global data set represents an important reference for
clinicians treating and managing patients with IEIs in the context
of the COVID-19 pandemic.METHODS
A retrospective study was undertaken by a web-based survey, approved
by the University Hospitals Leuven Committee for Medical Ethics. The
questionnaire inquired about demographic data, COVID-19 presentation,
treatment, and outcomes in patients with IEIs (according to current
diagnostic guidelines) and documented SARS-CoV-2 infection. No identi-
fying information was required, while physicians were given the option of
providing their contact details. The survey opened on March 16, 2020, and
closed on June 30, 2020. An invitation to participate in the survey was
shared with members of various societies (European Society for Immuno-
deficiencies, Clinical Immunology Society, Latin American Society for
Immunodeficiencies, African Society for Immunodeficiencies, Asia Pacific
Society for Immunodeficiencies, Australasian Society for Clinical Immu-
nology & Allergy), as well as via the International Patient Organization for
Primary Immunodeficiencies, the Jeffrey Modell Foundation, and the
International Union of Immunological Societies Committee for Inborn
Errors of Immunity, with the aid of social media alerts. Fisher exact test of
independence and Bayesian analysis of contingency tables were used to
calculate the statistical significance of the correlation between categorical
variables.RESULTS
Patients
A total of 94 patients with an underlying primary immunode-
ficiency (PID)/IEI and infected by SARS-CoV-2, as determined
by serology (n 5 8) or diagnostic PCR (n 5 86), were reported
(Tables I and II). Male to female ratio was 1.8 to 1. Thirty-two pa-
tients were younger than 18 years and 62 were adults (median age
group, 25-34 years). Eleven patients have been reported
previously.19-21,23Types and causes of IEI
The distribution of patients according to IEI groups is shown in
Fig 1. Most patients had a pre-existing primary antibody defi-
ciency (53 of 94 [56%]), including
d 6 with X-linked agammaglobulinemia due to BTK variants
(patient [P] 18, P44, P50, P54, P57, and P58);
d 2 patients with heterozygous NFKB1 (P53 and P60) or
NFKB2 (P10 and P13) variants;
d 1 patient with X-linked severe combined immunodefi-
ciency (X-SCID) who underwent gene therapy 19 years
earlier that corrected his T cells but not B cells, thereby re-
maining antibody deficient (P43);
d 2 cases of autosomal-recessive (AR) agammaglobulinemia
(P11 and P64) (Fig 1 and Table II).
There were also 29 patients with common variable immune
deficiency (CVID) and 2 patients with syndromic features (P1:
cardiomyopathy and neutropenia; P41: ventricular septum defect
and CD41 T-cell lymphopenia; Table II). Forty-six of 53
antibody-deficient patients received immunoglobulin substitution
as standard therapy and 6 received immunosuppressive therapy.
Six patients had phagocyte defects: 4 with X-linked (variants in
CYBB [P8, P88, and P92]) or recessive (bialleic variants in NCF2
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with cyclosporin (Fig 1 and Table II). Fourteen patients had com-
bined immunodeficiencies (CIDs), including 10 with syndromic
features: Di George syndrome (P27); trisomy 21 (Down syn-
drome [P15, P17, and P26]),24,25 Wiskott-Aldrich syndrome
(P16: 3 months post–hematopoietic stem cell transplantation
[HSCT]; P35: 5 months post–gene therapy), ARPC1B deficiency
(P25), hyper-IgE syndrome due to heterozygous dominant
negative variants in STAT3 (P77 and P78), or biallelic variants
in PGM3 (P76). Other patients had pathogenic biallelic
variants in ZAP70 (P73) or IFNGR2 (P38), or heterozygous
gain-of-function variant in STAT1 (P93). P7 had chronic
mucocutaneous candidiasis and recurrent pyogenic sepsis, sug-
gesting an underlying innate immune defect. Nine patients pre-
sented with an immune dysregulation syndrome: autoimmune
polyendocrinopathy-candidiasis-ectodermal dystrophy (due to
biallelic AIRE variants [P87]); LRBA deficiency (P86); CTLA4
haploinsufficiency (P31 [post-HSCT, poor graft function] and
P32); autoimmune lymphoproliferation due to pathogenic
variants in PRKCD (biallelic; P84), or XIAP (P9, 4 months
post-HSCT); autoimmune lymphoproliferative syndrome
(ALPS)–like disease (P36 and P85); and prolidase deficiency
due to biallelic pathogenic variants in PEPD (P30) (Fig 1 and
Table II). The LRBA-deficient, PRKCD-deficient, X-linked in-
hibitor of apoptosis-deficient, ALPS-like, PEPD-deficient and 1
of the CTLA4-deficient patients (P32) received immunosuppres-
sive treatment (abatacept [n 5 2], mycophenolate [n 5 1], ste-
roids [n 5 3], sirolimus [n 5 2], everolimus [n 5 1]) (Table II).
Seven additional patients suffered from an autoinflammatory
disease (Fig 1 and Table II):
d Aicardi-Goutieres syndrome (AGS) due to biallelic RNA-
SEH2B variants (P81 and P82), treated with immunoglob-
ulin substitution and JAK inhibitors, or homozygous
SAMHD1pathogenic variants (P83);
d familial Mediterranean fever (MEFV variant [P28, P79, and
P80]), treated with anakinra, canakinumab, and/or colchi-
cine; and
d an autoinflammatory condition with lymphopenia and auto-
immune hemolytic anemia (AIHA), treated with steroids
(P29).
One patient suffered from bone marrow failure caused by
biallelic DNAJC21 mutations (P36), and 1 had pancytopenia due
to a heterozygous GATA2 variant (P94) (Fig 1 and Table II).
Before infection, all patients were stable on standard of care
treatment; 2 were on angiotensin-converting enzyme inhibitor
therapy. The most frequent presenting symptoms were fever
(69%) and cough (47%), followed by upper respiratory tract
symptoms (runny nose, sneezing: 19%) and shortness of breath/
dyspnea (13%). Gastrointestinal symptoms (diarrhea, vomiting)
and myalgia were reported in 14% and 16% of patients,
respectively, while acute respiratory insufficiency was the
presenting feature in 11% of patients. Other reported symptoms
were fatigue, sore throat, anosmia/ageusia, collapse, pallor, and
anemia.Clinical features of SARS-CoV-21 patients with IEI
Ten (11%) patients were asymptomatic (ALPS–like [P85],
AGS [P81 and P82], STAT1 gain-of-function [P93], Wiskott-
Aldrich syndrome [P35], ARCGD [P89], XLA [P56], ARagammaglobulinemia [P64], hypogammaglobulinemia [P40],
and CID [P74]), including 4 who had pre-existing lung disease
(Table II). In these cases, testing for SARS-CoV-2 was performed
only to enable travel, elective treatment, or due to positivity of a
symptomatic relative/close contact.
Twenty-four patients had mild disease and were treated as
outpatients (Table II). Two were 3-12 years old, 1 was 19-24
years, 6 were 25-34 years, 5 were 35-44 years, 3 were 45-54 years,
2 were 55-64 years, 4 were 65-74 years, and 1 was older than 75
years. These patients included
d 14 with predominantly antibody deficiency (11 with CVID,
of whom 7 had >_1comorbidity);
d 1 patient with X-SCID with persistent defective B-cell
function after gene therapy;
d 1 with activated PI3 kinase syndrome (P51, PIK3R1
mutation);
d 1 with CID with multiple autoimmune features (P75);
d 3 with hyper-IgE syndrome due to PGM3 deficiency (P76),
or STAT3 loss-of function (P77 and P78) including 1 with
chronic lung disease; and
d 2 with MEFV mutations (P79 and P80), 1 with AGS (P83,
SAMHD1 mutation), 1 with CGD due to CYBB mutation
(P92), and 1 with an unspecified phagocyte defect (P90).
Fifty-nine patients (63%) required hospitalization. Clinical
progression of 29 of these 59 patients evolved into respiratory
insufficiency (49% of hospitalized, 31% of all patients). Thirteen
patients required noninvasive ventilation/oxygen administration,
and 15 (11males, 4 females; 16% of all patients) were admitted to
intensive care units (ICUs) for invasive ventilation, including
extracorporeal membrane oxygenation (3 male patients, 2
succumbed, see below). In addition, individual patients were
admitted to ICU for severe AIHA (P36), hypotension (P94), or
MIS-C and miliary Mycobacterium avium infection (P38;
IFNGR2) but no respiratory complications. Among female pa-
tients admitted to ICU for respiratory insufficiency, 2 had CVID
and were aged 55-64 years (P3 and P4), 1 was older than 75 years
(hypogammaglobulinemia; P5), and one was younger than 2
years with trisomy 21 and chronic invasive ventilation via trache-
ostomy in the context of congenital heart disease (P17). In
contrast, the age distribution of the 11 affected males admitted
to ICU was broader than for females, and the general population
(Tables I and II):
d 1 aged 0-2 years (P8 [X-linked chronic granulomatous dis-
ease, X-CGD]);
d 2 aged 3-12 years (P15 [trisomy 21] and P16 [Wiskott-
Aldrich syndrome]);
d 2 aged 13-18 years (P13 [NFKB2] and P9 [XIAP]);
d 3 aged 35-44 years (P10 [NFKB2], P17 [agammaglobulin-
emia], and P1 [syndromic primary antibody deficiency]);
d P14, aged 45-54 years, and P12, aged 55-64 years, both
with CVID; and
d 1 patient 75 years or older (P6 [IgG2/IgA deficiency]).
The three patients with trisomy 21 experienced acute
respiratory insufficiency, requiring invasive (P15 and P17) or
noninvasive (P26) ventilation. P15 and P17 also had a pre-existing
heart condition; P17 required a tracheostomy and chronic
ventilation. Overall, 73% (11 of 15) of the patients needing
invasive ventilation had pre-existing comorbidities (Fig 1 and
Table II).
TABLE II. Summary of patients’ characteristics
Pt. no. Outcome PID
Age group
(y) Sex Comorbidities Usual therapy
Manifestations
Fever Cough URS GI Myalgia Other
1 Deceased Ab def.
Syndromic presentation




Ig, G-CSF X X Chest pain
2 Deceased Ab def.
CVID
35-44 F Kidney tx, lymphoma and
cervical cancer in remission
Ig, steroids Hypotension, renal failure
3 Deceased Ab def.
CVID
55-64 F Lung disease, heart
disease, ITP
Ig, rituximab, metoprolol X X Dyspnea, fatigue, hypotension,
renal failure
4 Deceased Ab def. CVID 55-64 F Lung disease Ig X X
5 Deceased Ab def.
IgG deficiency
>_75 F Lung disease, heart disease,
kidney disease,
hypertension, diabetes
Ig X X Dyspnea, hypotension, renal
failure
6 Deceased Ab def.
IgG2 and IgA deficiency
>_75 M Diabetes, AIHA Ig X Hypotension, renal failure
7 Deceased Ab def. CVID >_75 F Lymphoproliferative disease, GI
disease, genital tract
neoplasm
Ig Acute confusional syndrome
8 Deceased Phagocyte defects
CGD (CYBB)
0-2 M — — X Burkholderia sepsis
9 Deceased Immune dysregulation disorder
(XIAP)





10 Resolved Ab def. CVID (NFKB2) 35-44 M — Ig, antibiotics,
antivirals, mAb
X X X
11 Resolved Ab def. Agammaglobulinemia 35-44 M Lung disease Ig, steroids, antibiotics, GM-
CSF
X X X
12 Resolved Ab def. CVID 55-64 M Asthma Ig, immunosuppressive X X X
13 Resolved Ab def. CVID (NFKB2) 13-18 M Alopecia tot., psoriasis — X X X X Dyspnea
14 Resolved Ab def. CVID 45-54 M Lung disease Ig, immunosuppressive X X
15 Resolved CID
Trisomy 21






16 Still in ICU CID
Wiskott-Aldrich syndrome
3-12 M 3 mo post-HSCT, GI disease Antibiotics, Ig, steroids X X CMV encephalitis, anosmia
17 Still in ICU CID
Trisomy 21
0-2 F Heart defect, tracheostomy with
chronic ventilation
Antibiotics, Ig
18 Resolved Ab def. XLA (BTK) 3-12 M Spherocytosis Ig X X X Dyspnea, chest pain
19 Resolved Ab def. CVID 25-34 F — Ig X X Anosmia
20 Resolved Ab def. CVID 25-34 M — Ig X X X Fatigue
21 Resolved Ab def. CVID 45-54 M Lung disease Ig, antibiotics X X
22 Resolved Ab def. CVID 45-54 M Lung disease Ig, antibiotics X X X
23 Resolved Ab def.
Hypogammaglobulinemia
45-54 F Diabetes, heart disease,
hypertension, neuropathy,
mitochondrial myopathy










0-2 M Eczema, cow milk protein
allergy
Antibiotics, Ig X Collapse
26 Resolved CID
Trisomy 21




0-2 M Lung disease, tracheostomy
with chronic ventilation
Antibiotics, Ig X
28 Resolved Autoinflammatory disorder
(MEFV)
55-64 M Lung disease — X X X X Dyspnea
29 Resolved CID with immune dysregulation
and autoinflammation
35-44 M Hyporegenerative anemia,
AIHA, intermittent renal
insufficiency
Status post rituximab, steroids X X Dyspnea
Coinfection with CoV229E
30 Resolved Immune dysregulation disorder
(PEPD)





31 Resolved Immune dysregulation disorder
(CTLA4)





32 Resolved Immune dysregulation disorder
(CTLA4)





33 Resolved Ab def. CVID 35-44 M Lung disease Antibiotics, antivirals X X X Dyspnea, fatigue
34 Resolved Ab def.
Isolated IgG subclass def.
55-64 F Lung disease Antibiotics, Ig, omalizumab Dyspnea
35 Resolved CID
Wiskott-Aldrich syndrome




36 Resolved Immune dysregulation disorder
ALPS-like
13-18 M Immune thrombocytopenia Mycophenolate, eltrombopag X X Anemia, jaundice
37 Resolved CMC and recurrent sepsis 0-2 M — Ig X X X
38 Resolved MSMD
IFNGR2 deficiency
0-2 M — — X X Miliary Mycobacterium avium
coinfection, leukocytosis
39 Resolved Bone marrow failure
(DNAJC21)
3-12 M Exocrine pancreas insufficiency,
failure to thrive, cytopenias,
bone anomalies, mental
disability
Antibiotics, red blood cell
transfusions
X Increased anemia and
thrombocytopenia
40 Resolved Ab def.
Hypogammaglobulinemia
3-12 M Uveitis Ig Asymptomatic
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X ECMO ICU admission Pneumothorax, pulmonary
hypertension, heart failure
Antibiotics, steroids, Ig France
Hospital admission Renal failure Antibiotics, chloroquine,
enoxaparin, conv. plasma
USA
X X ICU admission Renal failure Antibiotics, chloroquine,
enoxaparin
USA
X X ICU admission Sepsis Antibiotics, steroids,
tocilizumab, lopinavir,
ritonavir
Italy No 17 d (until death) 17 d (until death)
X X ICU admission Renal failure Antibiotics, chloroquine,
enoxaparin
USA
X X ICU admission Renal failure Antibiotics, chloroquine,
enoxaparin
USA
Hospital admission E faecium sepsis, renal failure Antibiotics, chloroquine Spain
X ECMO ICU admission HLH Antibiotics, steroids France
X X ICU admission Sepsis, HLH Antibiotics, Ig Chile





X ECMO ICU admission HLH Antibiotics, steroids,
chloroquine, GM-CSF, conv.
plasma
Belgium 60-75 d 50 d
X X ICU admission Sepsis (Candida) Antibiotics, chloroquine,
remdesivir, lopinavir,
ritonavir, mAb
Italy No 4 wk





USA Yes 8 d
X X ICU admission — Steroids, chloroquine,
tocilizumab remdesivir,
lopinavir, ritonavir
Italy No 9 d
X X ICU admission HLH Antibiotics, steroids, Ig,
remdesivir
Germany
X X ICU admission Bacterial pneumonia Steroids, Ig Mexico
X X ICU admission — — Chile
X Admission with O2/NIV Bacterial pneumonia Antibiotics, remdesivir,
enoxaparin, conv. plasma
USA
X Admission with O2/NIV — Steroids, chloroquine,
tocilizumab, lopinavir,
ritonavir
Italy No 9-50 d
X Admission with O2/NIV — Antibiotics, steroids France No
X Admission with O2/NIV — Antibiotics, Ig France
X Admission with O2/NIV — Antibiotics France Yes (IgM) 2 mo
X Admission with O2/NIV — Antbiotics UK 15 d 18 d
X Admission with O2/NIV — Antibiotics, chloroquine Spain Yes 30 d 17 d
X Admission with O2/NIV — Antibiotics Mexico
X Admission with O2/NIV Neutropenia Antibiotics Belgium
X Admission with O2/NIV — Ig Chile
X Admission with O2/NIV — Steroids, lopinavir, ritonavir France
Hospital admission Anemia, neutropenia Chloroquine, lopinavir,
ritonavir, tocilizumab
Germany Yes 42 d 13 d
X Admission with O2/NIV Sepsis Antibiotics, steroids Italy
X Hospital admission — Chloroquine, remdesivir Spain
X Admission with O2/NIV — Steroids, aspirin, remdesivir USA
Hospital admission Bacterial pneumonia Antibiotics, lopinavir, ritonavir UK
Hospital admission Bacterial pneumonia Antibiotics, chloroquine Spain
Asymptomatic Mild myocarditis Chloroquine, lopinavir, ritonavir Italy Yes 41 d
Hospital admission AIHA Steroids USA
Hospital admission Bacterial pneumonia Antibiotics Belgium
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Pt. no. Outcome PID
Age group
(y) Sex Comorbidities Usual therapy
Manifestations
Fever Cough URS GI Myalgia Other
41 Resolved Ab def.
Syndromic presentation




42 Resolved Ab def.
CVID
13-18 M Lung disease Ig X X
43 Resolved Ab def. X-SCID after gene
therapy, residual B- cell
dysfunction (IL2RG)
19-24 M — Ig X X X X Anosmia, ageusia, fatigue
44 Resolved Ab def. XLA (BTK) 19-24 M Lung disease Ig X X Dyspnea
45 Resolved Ab def. CVID 25-34 M IBD Ig X X X
46 Resolved Ab def. CVID 25-34 M Lung disease Ig X X X X
47 Resolved Ab def. CVID 25-34 F Lung disease, AI disease Ig, antibiotics X X X Dyspnea
48 Resolved Ab def. CVID 25-34 M — Ig, antibiotics Sore throat
49 Resolved Ab def. CVID 25-34 M — Ig Anosmia, ageusia
50 Resolved Ab def. XLA (BTK) 25-34 M — Ig X X
51 Resolved Ab def.
APDS (PIK3R1)
25-34 F — Ig X Sore throat
52 Resolved Ab def. CVID 35-44 F — Antibiotics X X X
53 Resolved Ab def. CVID (NFKB1) 35-44 M Chronic diarrhea Ig X X X Dyspnea, fatigue
54 Resolved Ab def. XLA (BTK) 35-44 M — Ig X X
55 Resolved Ab def. CVID 35-44 F Lung disease Ig X
56 Resolved Ab def CVID 35-44 F Lung disease Ig, antibiotics X X X X Dyspnea, chest pain
57 Resolved Ab def. XLA (BTK) 45-54 M Lung disease, liver disease,
chronic skin and eye
conditions
Ig Asymptomatic
58 Resolved Ab def. XLA (BTK) 45-54 M Lung disease, liver disease Antibiotics, Ig X X Campylobacter jejuni
coinfection
59 At home Ab def. CVID 45-54 M Lung disease, kidney disease,
GI disease
Ig, steroids, mAb X
60 Resolved Ab def. CVID (NFKB1) 55-64 F Severe anemia Ig X X X Dyspnea, fatigue
61 Resolved Ab def.
CVID
55-64 M Lung disease,
lymphoproliferative disease
Ig X X X




63 Resolved Ab def. CVID 55-64 F Liver disease Ig X
64 Resolved Ab def. AR
agammaglobulinemia
55-64 M Lung disease Ig Asymptomatic
65 Resolved Ab def Hypogamma-
globulinemia
65-74 F Aortic coarctation Ig X X X X X
66 Resolved Ab def. CVID 65-74 F Diabetes, hypertension, obesity Antibiotics X X
67 Resolved Ab def. CVID 65-74 F — Ig, antibiotics X X Dyspnea
68 At home Ab def. CVID 65-74 F — — X X Fatigue
69 Resolved Ab def. CVID 65-74 F Diabetes, obesity, hypertension Antibiotics X X X Fatigue
70 Resolved Ab def. IgG deficiency >_75 M — Ig X X Dyspnea
71 Resolved Ab def.
Hypogammaglobulinemia
>_75 F Immune thrombocytopenia,
smoker, previous breast
cancer
Ig, antibiotics, ACE inhibitor,
simvastatin
X X Infected during hospital
admission for stroke
72 Resolved CID 3-12 F — Antibiotics X X X
73 Resolved CID (ZAP70) 13-18 F Lung disease, diffuse large B-
cell lymphoma
Ig, rituximab, brentuximab X X X
74 Resolved CID 13-18 F Heart defect Antibiotics, Ig Asymptomatic














25-34 M Lung disease, hypertension Antibiotics, antifungals X Headache
78 Resolved CID
Hyper-IgE (STAT3)
35-44 M GI and skin disease Antibiotics X Anosmia
79 Resolved Autoinflammation (MEFV) 35-44 F Amyloidosis Canakinumab, colchicine X X X X Dyspnea
80 Resolved Autoinflammation (MEFV) 45-54 F Amyloidosis Canakinumab, colchicine X X X
81 Resolved Autoinflammation
AGS (RNASEH2B)
3-12 M Mental disability — Asymptomatic
82 Resolved Autoinflammation
AGS (RNASEH2B)
3-12 M Mental disability — Asymptomatic
83 Resolved Autoinflammation
AGS (SAMHD1)
3-12 F Mental disability, spastic
quadriplegy, epilepsy
Sodium valproate, baclofen Rash on cheeks and arms
84 Resolved Immune dysregulation disorder
(PRKCD)




X X Rhinovirus coinfection
85 Resolved Immune dysregulation disorder
Somatic ALPS
3-12 F — Sirolimus Asymptomatic
86 Resolved Immune dysregulation disorder
(LRBA)
19-24 M Diabetes Abatacept, Ig, insulin X X X
87 Resolved Immune dysregulation
APECED (AIRE)









88 Resolved Phagocyte defects
CGD (CYBB)
3-12 M Hyporegenerative anemia Cyclosporine, antibiotics X X
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Hospital admission Incomplete HLH Antibiotics Germany Yes (IgG, IgA) 7 d
Asymptomatic — — Chile
Hospital admission — — Chile
Hospital admission — Ig, chloroquine Mexico
Not admitted — Antibiotics France
Hospital admission — Antibiotics, chloroquine,
enoxaparin, conv. plasma
USA
Not admitted — Antibiotics, chloroquine USA
NA — Antibiotics, chloroquine,
lopinavir, ritonavir
Spain
Hospital admission — Steroids, chloroquine,
enoxaparin
Brazil No 16-35 d
Not admitted — Antibiotics Argentina 41 d
Not admitted — — France Yes 2 wk
Hospital admission — Antibiotics, steroids, Ig,
chloroquine
Italy 64 d
Not admitted — — USA
Not admitted — — The Netherlands Yes 35 d
Hospital admission — Antibiotics, chloroquine,
enoxaparin
USA
Hospital admission — Antibiotics, chloroquine,
lopinavir, ritonavir
Italy 6-14 d
Not admitted — Antibiotics Spain No 6-38 d 14 d
Hospital admission — Steroids, chloroquine Brazil
Asymptomatic — — Spain
Hospital admission — — Spain
Not admitted — — NA
Hospital admission — Antibiotics, chloroquine,
enoxaparin
USA
Not admitted — Chloroquine Spain
Hospital admission — Chloroquine, ivermectin,
anakinra
Germany Yes (IgM) 29 d 6 wk
Not admitted — — Germany No 58 d 2 wk
Asymptomatic — — Italy No 7 d
Not admitted — — France
Not admitted — Antibiotics France
Hospital admission — Antibiotics, chloroquine,
enoxaparin, conv. plasma
USA
Not admitted — — USA No >1 mo >1 mo
Not admitted — — France No 2 d
Not admitted — Antibiotics, chloroquine,
enoxaparin
USA
Hospital admission — Antibiotics UK 15-24 d 15 d
Hospital admission — Lopinavir, ritonavir Spain No 6 d
Hospital admission — — France Yes 36 d (still pos) 3 d
Asymptomatic — — Chile
Not admitted — Antibiotics UK Yes 3 d
Not admitted — — USA
Not admitted — — USA
Not admitted — — Spain Yes
Not admitted — Steroids, chloroquine Brazil
Not admitted — — Brazil
Asymptomatic — — France
Asymptomatic — — France
Not admitted — Antibiotics, aspirin UK Yes 15 d
Hospital admission — Antibiotics UK
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Age group
(y) Sex Comorbidities Usual therapy
Manifestations
Fever Cough URS GI Myalgia Other
89 Resolved Phagocyte defects
CGD (NCF2)
3-12 F Lung disease Antibiotics, antifungal Asymptomatic
90 At home Phagocyte defects 25-34 M Lung disease — X
91 Still in hospital Phagocyte defects 35-44 M — Antibiotics, antifungals, mAb X X Fatigue
92 Resolved Phagocyte defects
CGD (CYBB)
45-54 M Lung disease Antibiotics Anosmia
93 Resolved STAT1 GOF 03-12 F Lung disease Ig Asymptomatic
94 Resolved GATA2 deficiency 13-18 F Lung disease, bone marrow
hypoplasia, pancytopenia
Ig, steroids, antifungals, G-CSF X X Lower limbs edema, skin rash,
hypotension
Ab def., Antibody deficiency; ACE, angiotensin-converting enzyme; AI, autoimmune; AIHA, autoimmune hemolytic anemia; ALPS, autoimmune lymphoproliferative syndrome;
APECED, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy; conv., convalescent; def., deficiency; ECMO, extracorporeal membrane oxygenation; F, female; GI,
gastrointestinal; GOF, gain of function; GvHD, graft versus host disease; IBD, inflammatory bowel disease; ITP, immune thrombocytopenia; JCV, JC virus; M, male; MSMD,
Mendelian susceptibility to mycobacterial disease; NA, not available; NIV, noninvasive ventilation; pos., positive; Pt. no., patient number; Tx, treatment; URS, upper respiratory
symptoms; X-SCID, X-linked severe combined immune deficiency; XLA, X-linked agammaglobulinemia.
Choroquine and hydroxychloroquine are considered a single treatment group.
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infection
Reported complications, as defined according to international
guidelines26,27 or current practice,13,14 were bacterial pneumonia
(n 5 6), hemophagocytic lymphohistiocytosis (HLH) (n 5 6),
sepsis (n 5 6 [7%]), MIS-C (P38, IFNGR2, 1%), and kidney
failure (n 5 5 [5%]). Two patients had sepsis and HLH.
Furthermore, individual patients developed AIHA, thrombocyto-
penia, hyporegenerative anemia, neutropenia, myocarditis, and
heart failure.
Nine patients in this cohort (7 adults and 2 children, 10%) died
(Fig 1 and Table II): 4 males (0-2 years: n5 1; 13-18 years: n5 1;
35-44 years: n 5 1; >75 years: n 5 1), 5 females (35-44 years:
n 5 1; 55-64 years: n 5 2 ; >_75 years: n 5 2). The child aged
0-2 years (P8, Table II) had X-CGD, concomitant Burkholderia
sepsis, and HLH. The other child (P9, 13-18 years) had severe
gut graft versus host disease following HSCT for XIAP deficiency
and developed septic shock and HLH. Thus, it is unclear how
much SARS-CoV-2 infection contributed to the death in both
children. P1 (male, 35-44 years) suffered a syndromic disease
with congenital dysmorphisms, mild developmental delay,
hypogammaglobulinemia, neutropenia, hypertrophic cardiomy-
opathy, and bronchopathy. He developed pneumothorax,
pulmonary hypertension, and heart failure after SARS-CoV-2
infection and died despite treatment with antibiotics, immuno-
globulin infusion, steroids, and extracorporeal membrane
oxygenation. The other deceased patients (5 females and 1
male) suffered from antibody deficiencies (CVID [P2, P3, P4,
and P7]; isolated IgG deficiency [P5]; IgA and IgG2 deficiency
[P6]; Table II). Most patients were treated for potential bacterial
coinfection or superinfection with antibiotics and extra
immunoglobulin infusion.
All adult patients with PID who succumbed to SARS-CoV-2
infection had pre-existing comorbidities (Fig 1 and Table II): P1
had cardiomyopathy and developed pulmonary hypertension and
heart failure; P2 had chronic kidney disease, underwent kidney
transplant, and had several malignancies; all other patients were
older than 55 years, and P3 had chronic lung and heart disease;
P4 had chronic lung disease and developed sepsis; P5 had chronic
lung, heart, and kidney disease, hypertension, and diabetes; P6
had diabetes; P7 had lymphoproliferative disease, gastrointestinal
disease, and genital tract neoplasm and developed Enterococcus
faecium sepsis. P2, P3, P5, P6, and P7 all developed hypotension
and kidney failure during COVID-19. However, exact cause of
COVID-19–related deaths for these patients is unknown.Treatments of SARS-CoV-2 infection in patients
with IEI
Therapeutic strategies varied greatly and consisted of the
following medications, alone or in combination: antibiotics
(51%), immunoglobulin replacement (10.6%), hydroxychloro-
quine/chloroquine (33%), systemic steroids (21%), mAbs (8.5%,
tocilizumab [n 5 6] and anakinra [n 5 1]), antivirals (lopinavir
and ritonavir 12.7%, remdesivir 9.6%, favipravir 1%), and
enoxaparin (12.7%). Five patients (2 in ICU) received convales-
cent plasma and other treatments (antibiotics, chloroquine,
remdesivir, steroids, enoxaparin, tocilizumab), with 4 surviving.
Six patients were treated with tocilizumab, 4 in ICU, 1 of whom
died of infection. (Hydroxy)chloroquine was administered to 31
patients (5 succumbed), and remdesivir to 9 patients, 5 of whom
required admission to ICU and invasive ventilation, all of whom
survived.
The association between outcome (alive/dead) and the onset of
respiratory insufficiency, the presence of comorbidities, or the sex
of the patient was not significantly different between patients who
survived or patients who succumbed to SARS-CoV-2. Moreover,
no correlation could be found between outcome and respiratory
insufficiency, age groups, or PID type. Individual patient
categories were too small to allow for multivariate analysis.DISCUSSION
Individuals with IEIs, and subsequent immune deficiency or
immune dysregulation, are a priori considered an at-risk popula-
tion for developing severe COVID-19 following SARS-CoV2
infection. Although a few studies have reported outcomes of
SARS-CoV-2 infection in small numbers of patients with
PID,19-22 the impact of the COVID-19 pandemic on the broader
global population of these patients has not been established.
Here, we report the occurrence and course of SARS-CoV-2 infec-
tion in 94 patients with IEI. Distribution between diagnostic IEI
categories reflected that of large patient registries (esidregistry.
org; usidnet.org). Thus, patients with antibody deficiencies are
the predominant group with COVID, and approximately 20% of
patients had CIDs or impaired innate immunity (Fig 1).
Overall, presentation and risk factors (eg, pre-existing heart,
lung, or kidney disease) for severe COVID-19 in patients with IEI
seem very similar to those in the general population. Case-fatality
rate was approximately 10%, in line with global data from the
general population (1%-20%, Table I).1,10,28,29 The mortality rate











Asymptomatic — — France Yes 42 d (still pos.) 28 d
Hospital admission — Antibiotics France
Hospital admission — Antibiotics France
Hospital admission — Antibiotics France <1 mo
Asymptomatic — — UK
Not admitted — — USA
Hospital admission — Chloroquine Spain
Not admitted — Antibiotics Mexico Yes
Asymptomatic — — Chile Yes (IgM) 21 d
Hospital admission — Antibiotics, steroids, Ig Chile
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kholderia infection in P8 [X-CGD]; severe graft versus host dis-
ease in P9 [XIAP deficiency, post-HSCT]). Thus, perhaps
surprisingly, the inherent immunocompromised state of the pa-
tients studied here was generally not a predominant risk factor
for severe COVID-19. Similar to some epidemiological ana-
lyses,28 there was a male predominance among all patients with
IEI (1.8:1), as well as those admitted to ICU (2.8:1). The sex ratio
among patients with CVID with a more severe course (requiring
at least oxygen) was also strongly skewed toward males (M:F,
8:5). However, there are apparent differences in the age distribu-
tion of patients with IEI affected by SARS-CoV-2 (median age,
25-34 years) as well as the frequency of ICU admissions (16%)
compared with the general population (Table I).10 Our study sug-
gests that youngermale patients with IEI aremore likely to endure
severe COVID-19 and require ICU admission. This skewing is not
explained by the inclusion of X-linked disorders in this cohort
(n 5 13). Rather, differential levels of inflammatory mediators,
T-cell responses, and/or virus-specific antibodies between in-
fected males and females may explain the predominance of males
with severe COVID-19.30
One of the key findings from our study is the identification of
both redundancies in the human immune system for host defense
against SARS-CoV-2 and putative mediators of immune pathol-
ogy following viral infection. First, many patients with defects
predominantly in the adaptive immune system (eg, defective
humoral [XLA, agammaglobulinemia, persisting humoral immu-
nodeficiency in X-SCID after gene therapy] and/or T-cell [ZAP70,
PGM3, STAT3, ARPC1B mutations] responses) were either
asymptomatic or had only mild disease and promptly recovered
(Table II; see references 19-22). Similarly, 11 patients with
CVID had mild disease and did not require hospital admission,
despite several having comorbidities. Thus, certain components
of adaptive immunity do not appear to be essential for controlling
SARS-CoV-2 infection. Rather, these adaptive immune defi-
ciencies may even contribute to a milder course by reducing the
immune-mediated sequelae. This is consistent with findings that
patients with IEIs that specifically affect B- and T-cell develop-
ment or function do not exhibit increased susceptibility to severe
disease caused by influenza infection.31,32 Our findings thatpatients with CVID comprised a large proportion of our cohort
(>30%), and that 4 of these patients died (45% of all deaths),
may infer that intact humoral immunity is important for host de-
fense against SARS-CoV-2. However, these patients were gener-
ally older than the rest of the cohort (median age range, 45-54
years), and many had pre-existing health conditions that predis-
pose to severe COVID-19 in the general population (lung disease
in ;50%, kidney/heart/gut/liver disease in ;20%; Table II).
Second, with the exception of the patient with X-CGD with
Burkholderia sepsis, the other 3 patients with CGD had relatively
mild disease, suggesting a modest contribution of neutrophil
function in anti–SARS-CoV-2 immunity.
Third, mild or asymptomatic disease in SARS-CoV-21 patients
with dominant negative STAT3 variants, despite pre-existing
chronic lung disease, suggests that STAT3 signaling contributes
to the cytokine storm characteristic of severe COVID-19.
Together with findings that serum IL-6 levels are greatly
increased during SARS-CoV-2 infection,6,33-35 and predict mor-
tality in severe COVID-19,36,37 our data suggest that IL-6/
STAT3 contributes to the inflammatory response and subsequent
disease severity in COVID-19. Based on this, mild disease in
XLA may reflect not only B-cell deficiency but also impaired
IL-6 production by BTK-deficient myeloid cells,38 potentially
ameliorating SARS-CoV-2–induced cytokine storm.
Fourth, all patients with autoinflammatory diseases were
asymptomatic or stayed at home. However, most of these patients
were young children, and both adults were treated with IL-1
blockade and colchicine.
Two recent studies provide convincing evidence that disruption
of type I IFN signaling is a frequent cause of life-threatening
COVID-19.39,40 In the first study, 650 patients with life-
threatening COVID-19 were studied by whole-exome sequencing
under the hypothesis that severe COVID-19 is allelic with severe
influenza39 or that genes biologically related to these loci would
be involved.31,32 Indeed, 3.5% of patients had known (AR IRF7
and IFNAR1 deficiency, autosomal-dominant TLR3, TICAM1,
TBK1, and IRF3 deficiency) and new (autosomal-dominant
UNC93B1, IRF7, IFNAR1, and IFNAR2 deficiency) genetic de-
fects abolishing induction or amplification of type I IFNs.39 In
the second study, neutralizing autoantibodies against type I
FIG 1. Distribution of patients based on IEI category, comorbidities, and
outcome. Shaded colors indicate patients who succumbed to COVID-19 in
that IEI group. The numbers of patients (alive and deceased) are indicated
for each individual subcategory on the figure. A, Ambulatory; H, hospital-
ized; NIV/O2, noninvasive ventilation/oxygen; ‘‘1,’’ with comorbidities;
‘‘2,’’ no comorbidities.
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COVID-19 pneumonia, resulting in low or undetectable serum
levels of IFN-a during acute disease; 94% of the patients with au-
toantibodies were male. The net result of both the anti-IFN auto-
antibodies and the loss-of-function variants in crucial type I IFN
pathway genes is a profound defect in type I IFN immunity, un-
derlying life-threatening COVID-19 pneumonia.
Intriguingly, we observed mild disease in patients with
interferonopathies (AGS) treated with JAK inhibitors, suggesting
sufficient residual type I IFN to protect from severe initial
infection. It was striking that patients withNFKB1 orNFKB2mu-
tations required hospitalization, with both NFKB2-deficient indi-
viduals being admitted to ICU (Table II). Because the canonical
and alternate NFKB pathways are activated in plasmacytoid den-
dritic cells to produce large amounts of type 1 IFNs,41 severe
COVID-19 in patients with NFKB1 or NFKB2 loss-of-function
variants may be explained by deficient type I IFN responses.
Similarly, an absence of type 1 IFN-producing myeloid cells
may underlie COVID-19 due to GATA2 haploinsufficiency
(Table I).42 Because autoimmunity is a frequent manifestation
of CVID, it can be hypothesized that the presence or absence of
anti–type I IFN autoantibodies predisposed patients with CVID
to either life-threatening or mild disease after SARS-CoV-2 infec-
tion. The finding of neutralizing anti-IFN autoantibodies in some
individuals with severe COVID-1940 may also explain why pa-
tients with agammaglobulinemia generally did not develop severe
COVID-19, and predict that COVID-19 may occur in some
AIRE-deficient patients because these patients produce autoanti-
bodies against type 1 IFNs.43 Moving forward, it will be impor-
tant to not only study the functionality of immune cells from
patients with IEI in the context of innate IFN signaling but also
assess these patients for neutralizing anti–type 1 IFN antibodies.
Several caveats of our study need to be recognized. First,
asymptomatic or mildly symptomatic SARS-CoV-2–infected
patients with IEI are likely to be underdiagnosed, mainly due to
regional testing priorities contributing to an ascertainment bias of
such a retrospective study. Second, becausewewere guided by the
most recent update of IEI,16-18 it is unlikely that all patients withIEI who have been infected with SARS-CoV-2 were captured by
our survey. Indeed, the field of IEI continues to grow rapidly, with
more than 35 novel genetic defects having been described since
the last update by the International Union of Immunological So-
cieties committee. Thus, we have not considered SARS-CoV-2
infection in individuals with these putative novel monogenic
causes of immune dysregulation. Third, if our survey accurately
reflects the true incidence of COVID-19 in IEI, it suggests that
immunodeficient patients have been less frequently infected and
are less symptomatic than the general population. This could be
explained by patients with IEI being informed early in the
pandemic about safety measures by patient and scientific organi-
zations. Moreover, patients with IEI are familiar with frequent
sanitation practices, avoiding crowds, physical distancing, self-
isolation, and so forth, as recommended during this pandemic.
Fourth, our study does not include any patients with known de-
fects of type I IFN pathways. On the basis of findings from studies
of severe influenza,31,32 and recent investigation of the genetics of
life-threatening SARS-CoV-2 infection,39 these patients are even
more strongly advised to practice strict hand hygiene, mask wear-
ing, and social distancing than other patients with PID.Conclusions
We report the course of COVID-19 in 94 patients with IEI. The
survey revealed that a substantial subgroup of patients with IEI
suffer only a mild course of disease. Risk factors predisposing to
severe disease and mortality among patients with IEI were compa-
rable to those in the general population. However, younger patients
with IEI were more severely affected and more frequently admitted
to ICU compared with the general population. These findings
warrant recommendation for further stringent personal protective
measures for patients affected by IEI. The urgent need to document
the impact of SARS-CoV-2 on patients with defined IEIs is
currently being met by registries developed by additional organi-
zations (eg, ESID registry, ERN-RITA joint effort, and COPID19),
as well as the COVID Human Genetic Effort, which is performing
large-scale genetic and functional studies on patients affected by
severe COVID-19.15,39,40 Ideally, these studies will also include
prospective longitudinal analysis to determine the long-term impact
of SARS-CoV-2 even in convalescent individuals. These initiatives
will further our insight into susceptibility of individual patients with
IEI to disease. This will not only reveal necessary and redundant
pathways for host defense against SARS-CoV-2 but also identify
those that mediate collateral tissue damage in response to viral
infection. Collectively, this and future studies have the potential to
provide opportunities for immune modulation to treat COVID-19
in patients with IEI as well as the general population.
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Clinical implications: Risk factors predisposing to severe dis-
ease and mortality after SARS-CoV-2 infection in patients
with IEI were similar to those in the general population.
Notwithstanding inclusion and diagnostic bias, admission rates
to ICU tended to be higher and median age of affected patients
lower than in the general population.
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